HomeIUGNF • OTCMKTS
add
Imugene Ltd
Previous close
$0.042
Day range
$0.040 - $0.052
Year range
$0.020 - $0.11
Market cap
497.85M AUD
Avg Volume
103.02K
P/E ratio
-
Dividend yield
-
Primary exchange
ASX
Market news
Financials
Income Statement
Revenue
Net income
(AUD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | 4.03M | 67.62% |
Operating expense | 39.54M | 248.59% |
Net income | -34.36M | -295.08% |
Net profit margin | -851.69 | -135.70% |
Earnings per share | — | — |
EBITDA | -34.58M | -312.56% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(AUD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 139.39M | -13.91% |
Total assets | 230.42M | 8.41% |
Total liabilities | 35.59M | 592.44% |
Total equity | 194.83M | — |
Shares outstanding | 7.17B | — |
Price to book | 1.40 | — |
Return on assets | -38.52% | — |
Return on capital | -44.09% | — |
Cash Flow
Net change in cash
(AUD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -34.36M | -295.08% |
Cash from operations | -25.44M | -141.18% |
Cash from investing | -6.97M | -2,923.96% |
Cash from financing | 25.16M | -39.59% |
Net change in cash | -6.88M | -122.18% |
Free cash flow | -27.09M | -384.72% |
About
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Imugene's unique platform technologies seeks to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.
The company's product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours.
Imugene is a publicly traded company, listed on the Australian Securities Exchange under the code IMU. In December 2021 it entered the S&P/ASX 200 Index, in effect making it one of the 200 largest companies on the ASX. Wikipedia
CEO
Founded
2012
Website